INTRODUCTION
============

Prostate cancer (PCa) is the most common solid organ malignancy and the second most common cause of cancer-related death among men in industrialized nations \[[@b1-pi-1-3-102-2]\]. Prostate-specific antigen (PSA) is the most widely used serum marker that has revolutionized the early detection and management of PCa \[[@b2-pi-1-3-102-2],[@b3-pi-1-3-102-2]\]. However, the relative lack of cancer-specificity, without upper or lower threshold values, is a major drawback that may lead to unnecessary risks and costs \[[@b1-pi-1-3-102-2]\].

Various attempts have been made to overcome these limitations, namely, the utilization of PSA density (PSAD), percentage of free PSA, PSA velocity, age-specific PSA ranges, complex PSA, and transition zone (TZ) PSAD \[[@b4-pi-1-3-102-2]--[@b6-pi-1-3-102-2]\]. However, none of these indexes has achieved satisfactory results applicable to everyday clinical practice. The interpretation of PSA is even more complex in patients with benign prostatic hyperplasia who are administered 5α-reductase inhibitors (5ARIs). 5ARIs have been shown to reduce prostate volume (PV) by approximately 20% and to decrease serum PSA levels by about 50% on a 6-month course \[[@b7-pi-1-3-102-2]\]. It is generally accepted that the sensitivity and the specificity of serum PSA levels can be maintained by doubling the patient's PSA value to account for the change in PSA \[[@b8-pi-1-3-102-2]\]. However, this is a rough estimation that does not exactly reflect the biological variability in PSA between individuals.

To address these issues, in the present study, various volume-adjusted PSA parameters were derived and analyzed for predictive performance in the detection of PCa. Furthermore, in an attempt to investigate whether these volume-adjusted indicators may account for the changes in PV, these parameters were analyzed and compared between patients who had been receiving 5ARIs for over 6 months and patients who were naïve to 5ARIs. Our findings indicate that volume-adjusted PSA parameters are more reliable than PSA in discriminating PCa and that such parameters may reflect changes in prostate volumetrics in patients administered 5ARIs.

MATERIALS AND METHODS
=====================

1.. Patients
------------

The results of 3,520 consecutive prostate biopsies performed between May 2006 and January 2013 were retrospectively assessed. The median age of the patients was 67.5 years (range, 31 to 90 years). The inclusion criteria were patients who underwent 12-core to 14-core prostate biopsy. Patients with inadequate transrectal ultrasonography (TRUS) images with an ambiguous boundary between the peripheral zone (PZ) and the TZ, an indefinite history of prior medications, or a pathological diagnosis of prostatic intraepithelial neoplasia or atypical small acinar proliferation were excluded from the study cohort. Patients who had received 5ARIs for more than 6 months were identified and designated as group A. Each group A patient was randomly matched with three patients naïve to 5ARIs with adjustment for age, who were designated as group B. The study was carried out in accordance with the Institutional Review Board practice guidelines.

2.. Measurements of PSAD-based parameters
-----------------------------------------

TRUS was used to measure the total PV and the TZ volume (TZV) by use of the formula for a prolate ellipsoid (length× width×height×0.52). The PZ volume (PZV) was measured by subtracting TZV from PV. PSAD, PZPSAD, and TZPSAD were calculated by dividing PSA by PV, PZ, and TZ, respectively.

3.. Statistical analysis
------------------------

Comparisons between groups were performed by using Student *t*-test. Areas under the ROC curves (AUCs) were used to calculate performances of PSA, PSAD, PZPSAD, and TZPSAD in detecting PCa and high-grade disease, defined as a Gleason score sum ≥7. Pairwise comparisons of ROC curves were used to compare predictive performances between each volume-adjusted PSA parameter. All statistical analyses were performed by using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA) and MedCalc ver. 11.6 (MedCalc Software, Acacialaan, Ostend, Belgium). Statistical significance was set at *P*\<0.05.

RESULTS
=======

1.. Demographic data of investigated subjects
---------------------------------------------

Among 1,164 eligible patients, group A consisted of 291 patients (25%), and group B consisted of 873 patients (75%). Overall, PCa was histologically diagnosed in 345 patients (29.6%). The clinical characteristics of the overall cohort are presented in [Table 1](#t1-pi-1-3-102-2){ref-type="table"}. Patients in whom PCa was diagnosed were older; had higher PSA, PSAD, PZPSAD, and TZPSAD; and had significantly lower PV, PZV, and TZV than did patients with benign pathology. The clinical characteristics of the patients according to group stratification are shown in [Table 2](#t2-pi-1-3-102-2){ref-type="table"}. PCa was histologically confirmed in 65 group A patients (22.3%) and in 280 group B patients (32.1%).

2.. Logistic regression analysis on predictive values by use of volume-adjusted PSA parameters
----------------------------------------------------------------------------------------------

Univariate logistic analyses were performed for volume-adjusted PSA parameters ([Table 3](#t3-pi-1-3-102-2){ref-type="table"}). All volume-adjusted PSA parameters were significant predictors for the detection of PCa in both cohorts. Multivariate regression analysis revealed that PSA (odds ratio \[OR\], 0.959; *P*=0.021) and PSAD (OR, 84.81; *P*=0.033) were significant independent predictors for detecting PCa for the overall population. In group A, PZPSAD (OR, 43.18; *P* =0.017) remained the only independent predictor, whereas in group B, PSA (OR, 0.957; *P* =0.038) was an independent parameter ([Table 4](#t4-pi-1-3-102-2){ref-type="table"}).

3.. Analysis by ROC curves
--------------------------

ROC analyses of volume-adjusted PSA parameters in the detection of PCa are shown in [Table 5](#t5-pi-1-3-102-2){ref-type="table"} and [Fig. 1](#f1-pi-1-3-102-2){ref-type="fig"}. The ROC curves of group A showed that PZPSAD had the highest accuracy for discriminating PCa, followed by PSAD, TZPSAD, and PSA. PSAD and PZPSAD revealed significantly higher AUCs than that of PSA, whereas the superiority of PZPSAD compared with PSAD was statistically significant (*P*=0.039). The sensitivities of the two highest predictors, i.e., PSAD and PZPSAD, at a set specificity of 40%, were 84% and 88%, respectively. In group B, PSAD and PZPSAD showed significantly higher AUCs than did PSA (*P*\<0.001); however, the AUC of PZPSAD failed to significantly surpass that of PSAD (*P*=0.321). TZPSAD showed no better accuracy than PSA. The sensitivities of the two highest predictors, i.e., PSAD and PZPSAD, at a set specificity of 40%, were 81% and 79%, respectively.

ROC analyses of volume-adjusted PSA parameters in detecting high-grade PCa are shown in [Table 6](#t6-pi-1-3-102-2){ref-type="table"} and [Fig. 2](#f2-pi-1-3-102-2){ref-type="fig"}. PZPSAD revealed the highest AUC in group A but did not meet statistical significance compared with PSAD, which revealed the second highest AUC. A notable finding was that PSA was significantly inferior to all volume-adjusted parameters for detecting PCa. The sensitivities of the two highest predictors, i.e., PSAD and PZPSAD, at a set specificity of 40%, were 85% and 87%, respectively. In group B, PSA showed the highest AUC for discriminating high-grade disease. The sensitivity of PSA at 40% specificity was revealed to be 76%.

DISCUSSION
==========

It is generally accepted that PSA provides the highest diagnostic performance for PCa and that its application to clinical practice has revolutionized the management of this disease \[[@b2-pi-1-3-102-2]\]. However, the major drawback is its lack of cancer specificity and the lack of an upper or lower threshold value \[[@b9-pi-1-3-102-2],[@b10-pi-1-3-102-2]\]. False elevations in noncancerous conditions not only result in unnecessary biopsies that lead to potential complications, but often mask aggressive forms of cancer that may lead to substantial harm \[[@b1-pi-1-3-102-2]\]. This ongoing clinical challenge has aroused scientific challenges to evaluate novel biomarkers sensitive to PCa, namely, genetic-based, serologic, and urinary markers \[[@b11-pi-1-3-102-2]\]. However, to date, none of these biomarkers has clearly outweighed diagnostic benefits against drawbacks. The present study did not seek to settle these concerns, but to raise the possibility that controlling for confounding conditions that can affect PSA values, such as benign prostatic enlargement, may confer additional diagnostic value. Indeed, developing a strategy of utilizing clinical parameters that are routinely evaluated, i.e., serum PSA and PV measurement by TRUS, could be of benefit in terms of cost, time, and treatment decision making.

The present study utilized volume-adjusted PSA-based parameters in an attempt to enhance the predictive performance of PSA. Kalish et al. \[[@b12-pi-1-3-102-2]\] first introduced the concept of utilizing the volume-adjusted PSA-based parameter TZPSAD to show its superiority in discriminating PCa compared with PSAD. Validation studies have been performed by Kang et al. \[[@b13-pi-1-3-102-2]\] showing that TZPSAD may be more effective in patients with intermediate PSA levels. Furthermore, Djavan et al. \[[@b14-pi-1-3-102-2]\] reported that TZPSAD was more useful in patients with prostates larger than 30 g. However, Tanaka et al. \[[@b15-pi-1-3-102-2]\], along with several other studies, showed that TZPSAD has an AUC similar to that of PSAD and disproved the usefulness of TZPSAD.

Alongside these investigations, our study is the first of its kind to utilize PZPSAD in addition to PSAD and TZPSAD as a potential predictive indicator for PCa and to compare these indexes between groups stratified according to 5ARI administration. We demonstrated that TZPSAD has a similar predictive value to PSAD in patients naïve to 5ARI and that its value is significantly below the level of PSAD in patients receiving 5ARIs. We further demonstrated that PZPSAD, among all volume-adjusted PSA parameters, had the significantly highest predictive value for detecting PCa in the 5ARI administration group. PZPSAD was also shown to be the most useful in the 5ARI-naïve group; however, it did not reach significance. In line with previous studies, PSA showed the lowest AUC compared with volume-adjusted PSA parameters.

The effectiveness of PSA and PSAD in detecting high-grade PCa (herein defined as a Gleason score sum ≥7) has been controversial. Elliot et al. \[[@b16-pi-1-3-102-2]\] reported a trend toward improved performance of PSA for both Gleason ≥7 and Gleason ≥8 diseases. Our study is consistent with previous results showing that PSA demonstrates the highest AUC for predicting high-grade PCa in patients naïve to hormonal manipulation \[[@b17-pi-1-3-102-2]\]. However, our study demonstrated the novel finding that in patients administered 5ARIs, the AUC for PSA falls significantly below that for all other volume-adjusted PSA parameters.

A logical question that could be raised by our findings is, "Why would PZPSAD be a better indicator for PCa in patients administered 5ARIs?" A possible answer is that patients receiving 5ARIs would have larger PV and higher PSA levels owing to the relative enlargement of TZV. To the best of our knowledge, no study to date has investigated changes in differential prostate zonal volumes in patients administered 5ARIs. However, it can be presumed that 5ARI has a relatively greater effect on the reduction of TZV and a modest effect on PZV, because TZ accounts for a greater proportion of the total PV in benign prostatic enlargement \[[@b18-pi-1-3-102-2]\]. This volume reduction effect may have suppressed PSA owing to benign prostatic hyperplasia and thus led to a greater separation in PZPSAD values compared with values in those who actually harbored PCa. Indeed, PCa detected by a conventional PZ biopsy scheme as used in the present study would mostly reflect PZ cancers rather than TZ cancers. To clearly define the underlying mechanisms of these observations, investigations on relative zonal volume reductions according to administration of 5ARI should be undertaken.

The present study had several limitations that should be mentioned. First, the study was retrospective in nature. To confirm our findings, prospective and randomized studies with larger populations will be needed. Second, we could not exactly determine whether a patient harbors PCa because a prostate biopsy may miss 20% of PCa considered to be clinically significant and, conversely, may detect insignificant cancers \[[@b19-pi-1-3-102-2],[@b20-pi-1-3-102-2]\]. Third, volume-adjusted PSA measurements necessitate PV determinations that are not always available in clinical practice. Last, our study cohort was not based on a general population as a whole but on a database of patients obtained from a single, tertiary institution. Therefore, our results may include a selection bias in which the results may not be applicable to the whole population.

In conclusion, volume-adjusted PSA parameters could be more useful than PSA in detecting PCa. For patients receiving 5ARI for more than 6 months, PZPSAD conferred the highest diagnostic performance in predicting PCa and high-grade disease. In patients naïve to 5ARIs, PSA remained superior to PSAD or PZPSAD in predicting high-grade disease but showed the lowest value for discriminating PCa.
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###### 

Clinical characteristics of the overall cohort

  Parameter     Total               Group A             Group B              *P*-value
  ------------- ------------------- ------------------- -------------------- -----------
  Patients      1,164               291 (25)            873 (75)             
  Age (yr)      67.5 (31--90)       67.3 (31--90)       67.8 (39--90)        0.474
  PSA (ng/mL)   6.5 (2.6--19.8)     6.4 (2.6--19.4)     6.6 (2.7--19.8)      0.707
  PSAD          0.15 (0.02--0.75)   0.13 (0.02--0.72)   0.15 (0.02--0.75)    0.001
  PV (mL)       43.8 (8.1--263.9)   51.1 (8.1--188.7)   40.1 (12.5--263.9)   \<0.001
  PZV (mL)      18.9 (1.4--93.4)    20.6 (3.4--93.4)    18.1 (1.4--79.1)     0.001
  TZV (mL)      23.4 (4.2--184.8)   26.6 (4.7--118.3)   21.3 (4.2--184.8)    \<0.001
  PZPSAD        0.36 (0.04--2.81)   0.39 (0.04--1.54)   0.35 (0.04--2.81)    0.024
  TZPSAD        0.26 (0.03--2.32)   0.23 (0.03--1.46)   0.28 (0.03--2.32)    0.001
  DRE (+)       209 (17.9)          45 (15.5)           164 (18.8)           0.072
  TRUS (+)      141 (12.1)          36 (12.4)           105 (12.1)           0.456

Values are presented as number (%) or median (range).

PSA, prostate-specific antigen; PSAD, PSA density; PV, prostate volume; PZV, peripheral zone volume; TZV, transition zone volume; PZPSAD, peripheral zone PSAD; TZPSAD, transition zone PSAD; DRE, digital rectal examination; TRUS, transrectal ultrasonography.

###### 

Clinical characteristics of group A (patients on 5ARI) and group B (patients naïve to 5ARI)

  Parameter      Group A (n=291)      Group B (n=873)                                                          
  -------------- -------------------- -------------------- --------- -------------------- -------------------- ---------
  Patients       65 (22.3)            226 (77.7)                     280 (32.1)           593 (68.5)           
    Low grade    30 (46.2)                                           135 (48.2)                                
    High grade   35 (53.8)                                           145 (51.8)                                
  Age (yr)       69.3 (51--81)        66.2 (31--90)        0.002     68.5 (39--87)        65.1 (39--90)        \<0.001
    Low grade    69.0 (51--81)                             0.186     67.9 (47--80)                             0.009
    High grade   70.2 (56--81)                             0.029     69.8 (39--87)                             \<0.001
  PSA (ng/mL)    6.9 (3.3--18.5)      6.3 (2.6--19.4)      0.001     7.0 (3.1--19.5)      6.3 (2.7--19.8)      0.001
    Low grade    6.8 (3.3--18.5)                           0.376     6.1 (3.1--19.1)                           0.498
    High grade   8.1 (4.1--17.8)                           0.071     8.1 (3.3--19.5)                           \<0.001
  PSAD           0.17 (0.04--0.61)    0.12 (0.02--0.72)    \<0.001   0.18 (0.04--0.75)    0.14 (0.02--0.72)    \<0.001
    Low grade    0.19 (0.06--0.53)                         0.002     0.17 (0.04--0.71)                         0.052
    High grade   0.17 (0.04--0.61)                         \<0.001   0.22 (0.05--0.75)                         \<0.001
  PV (mL)        40.1 (8.1--112.7)    53.9 (17.1--188.7)   0.004     36.5 (12.5--146.1)   44.4 (13.6--263.9)   \<0.001
    Low grade    40.4 (15.3--112.7)                        0.008     36.9 (12.5--86.1)                         \<0.001
    High grade   39.4 (8.1--97.1)                          0.002     36.2 (12.7--146.1)                        0.002
  PZV (mL)       15.6 (3.4--33.9)     21.2 (6.1--93.4)     \<0.001   16.4 (1.4--44.1)     19.1 (3.6--79.1)     \<0.001
    Low grade    16.2 (8.9--30.7)                          0.035     16.2 (1.4--44.1)                          \<0.001
    High grade   15.3 (3.4--33.9)                          \<0.001   16.7 (5.9--43.1)                          \<0.001
  TZV (mL)       22.7 (4.7--87.7)     30.3 (4.8--118.3)    0.042     20.1 (4.9--103.0)    24.6 (4.2--184.8)    0.001
    Low grade    21.9 (6.4--87.7)                          0.011     20.7 (6.7--56.1)                          0.001
    High grade   23.1 (4.7--63.1)                          0.002     19.7 (4.9--103.0)                         0.021
  PZPSAD         0.49 (0.1--1.54)     0.31 (0.04--1.42)    0.001     0.43 (0.11--2.81)    0.32 (0.04--1.95)    \<0.001
    Low grade    0.54 (0.17--1.12)                         0.001     0.38 (0.11--2.81)                         0.004
    High grade   0.42 (0.12--1.54)                         \<0.001   0.51 (0.14--1.88)                         \<0.001
  TZPSAD         0.30 (0.07--1.03)    0.22 (0.03--1.46)    0.001     0.37 (0.06--1.46)    0.25 (0.03--2.32)    \<0.001
    Low grade    0.33 (0.09--1.03)                         0.011     0.32 (0.06--1.19)                         0.025
    High grade   0.29 (0.07--1.02)                         0.010     0.42 (0.07--1.46)                         \<0.001
  DRE (+)        20 (30.8)            25 (11.1)            \<0.001   93 (33.2)            71 (11.9)            \<0.001
    Low grade    9 (45.0)                                            39 (41.9)                                 
    High grade   11 (55.0)                                           54 (58.1)                                 
  TRUS (+)       22 (33.8)            14 (6.2)             \<0.001   73 (26.1)            32 (5.4)             \<0.001
    Low grade    13 (59.1)                                           32 (43.8)                                 
    High grade   9 (40.9)                                            41 (56.2)                                 

Values are presented as number (%) or median (range).

5ARI, 5α-reductase inhibitor; PSA, prostate-specific antigen; PSAD, PSA density; PV, prostate volume; PZV, peripheral zone volume; TZV, transition zone volume; PZPSAD, peripheral zone PSAD; TZPSAD, transition zone PSAD; DRE, digital rectal examination; TRUS, transrectal ultrasonography.

###### 

Univariate logistic regression analyses for volume-adjusted PSA parameters of each group

  Parameter   Group A   Group B                                     
  ----------- --------- ------------- --------- ------ ------------ ---------
  Age         1.07      1.03--1.11    \<0.001   1.06   1.03--1.08   \<0.001
  PSA         1.03      1.01--1.04    0.011     1.01   1.00--1.02   0.006
  PSAD        5.81      2.13--15.78   0.001     2.57   1.63--4.04   \<0.001
  PZPSAD      2.43      1.47--3.99    \<0.001   1.51   1.23--1.83   \<0.001
  TZPSAD      2.11      1.33--3.34    0.001     1.45   1.19--1.78   \<0.001

PSA, prostate-specific antigen; CI, confidence interval; PSAD, PSA density; PZPSAD, peripheral zone PSAD; TZPSAD, transition zone PSAD.

###### 

Volume-adjusted PSA parameters which showed significant predictive values in multivariate logistic regression analyses of each group

  Parameter            Odds ratio   95% CI          *P*-value
  -------------------- ------------ --------------- -----------
  Overall population                                
    PSA                0.959        0.927--0.993    0.021
    PSAD               84.81        1.421--5054.7   0.033
  Group A                                           
    PZPSAD             43.18        1.784--1045.1   0.017
  Group B                                           
    PSA                0.957        0.917--0.998    0.038

PSA, prostate-specific antigen; CI, confidence interval; PSAD, PSA density; PZPSAD, peripheral zone PSAD.

###### 

Receiver operating characteristic curve analyses of PSA, PSAD, PZPSAD, and TZPSAD in detecting prostate cancer according to each group

  Parameter   AUC     95% CI
  ----------- ------- --------------
  Group A             
    PZPSAD    0.781   0.712--0.839
    PSAD      0.751   0.679--0.811
    TZPSAD    0.717   0.645--0.782
    PSA       0.677   0.603--0.745
  Group B             
    PZPSAD    0.652   0.614--0.689
    PSAD      0.649   0.611--0.686
    TZPSAD    0.637   0.598--0.674
    PSA       0.582   0.543--0.621

The volume-adjusted PSA parameters are listed the order of their predictive performance. Group A: PZPSAD vs. PSAD, *P*=0.038; PSAD vs. TZPSAD, *P*\<0.001; TZPSAD vs. PSA, *P*=0.554. Group B: PZPSAD vs. PSAD, *P*=0.321; PSAD vs. TZPSAD, *P*=0.058; TZPSAD vs. PSA, *P*=0.756.

PSA, prostate-specific antigen; PSAD, PSA density; PZPSAD, peripheral zone PSAD; TZPSAD, transition zone PSAD; AUC, area under the curve; CI, confidence interval.

###### 

Receiver operating characteristic curve analyses of PSA, PSAD, PZPSAD, and TZPSAD in detecting high grade cancer according to each group

  Parameter   AUC     95% CI
  ----------- ------- --------------
  Group A             
    PZPSAD    0.625   0.487--0.731
    PSAD      0.614   0.476--0.742
    TZPSAD    0.601   0.462--0.731
    PSA       0.562   0.425--0.695
  Group B             
    PSA       0.715   0.647--0.776
    PSAD      0.667   0.597--0.731
    PZPSAD    0.662   0.593--0.727
    TZPSAD    0.661   0.591--0.726

The volume-adjusted PSA parameters are listed the order of their predictive performance. Group A: PZPSAD vs. PSAD, *P*=0.716; PSAD vs. TZPSAD, *P*=0.581; TZPSAD vs. PSA, *P*=0.038. Group B: PSA vs. PSAD, *P*=0.041; PSAD vs. PZPSAD, *P*=0.803; PZPSAD vs. TZPSAD, *P*=0.956.

PSA, prostate-specific antigen; PSAD, PSA density; PZPSAD, peripheral zone PSAD; TZPSAD, transition zone PSAD; AUC, area under the curve; CI, confidence interval.
